T-Cell-Mimicking Nanoparticles Can Neutralize HIV Infectivity

Area of Science:

• Biotechnology
• Immunology
• Virology

Background:

• Human immunodeficiency virus (HIV) infection remains a significant global health challenge.
• Developing effective and broad-spectrum HIV therapeutics is crucial for treatment and prevention.
• Existing strategies face challenges due to HIV's genetic diversity and potential for drug resistance.

Purpose of the Study:

• To develop a novel therapeutic strategy for HIV neutralization using cell-membrane coating technology.
• To create T-cell-membrane-coated nanoparticles (TNPs) that mimic natural CD4+ T cell interactions with HIV.
• To evaluate the efficacy of TNPs as decoy agents for viral neutralization.

Main Methods:

• Plasma membranes from CD4+ T cells were collected and coated onto polymeric cores to form TNPs.
• TNPs were designed to inherit T cell surface antigens (CD4, CCR5, CXCR4) for HIV binding.
• The binding affinity of TNPs to HIV gp120 and their neutralizing capacity against HIV infection were assessed in vitro.

Main Results:

• TNPs successfully mimicked T cell surface receptors, enabling selective binding to HIV gp120.
• TNPs demonstrated the ability to inhibit gp120-induced killing of bystander CD4+ T cells.
• TNPs effectively neutralized HIV infection in peripheral blood mononuclear cells and macrophages in a dose-dependent manner.

Conclusions:

• T-cell-membrane-coated nanoparticles (TNPs) represent a promising decoy strategy for HIV neutralization.
• This approach leverages natural host cell functions to overcome HIV genetic diversity and reduce selective pressure.
• TNPs hold significant potential as a novel therapeutic agent for combating HIV infection.